HomeAbout

TL;DR CNBC


FDA approves Merck's drug for rare, deadly lung condition - TL;DR CNBC

FDA approves Merck's drug for rare, deadly lung condition

Publishing timestamp: 2024-03-26 17:13:44


Summary

The FDA approved Merck's drug Winrevair to treat a rare lung condition, a win for both the drugmaker and patients. The drug is the first to target the root cause of the condition and is expected to be a significant growth driver for Merck.


Sentiment: POSITIVE

Tickers: MRK

Keywords: business newssciencemerck & co incfdabusinessbreaking newshealth care industrypharmaceuticalsbiotechnologybiotech and pharmaceuticals

Source: https://www.cnbc.com/2024/03/26/fda-approves-merck-drug-sotatercept-for-rare-deadly-lung-condition.html


Developed by Leo Phan